IL33 and inflammatory bowel disease: NFE2L3 deficiency leads to decreased expression of IL-33 in mast cells, activation of the RAB signaling pathway, and the inhibitory effect of Treg cells, all of which slow the progression of colitis and IBD-related colon cancer [135].